Protagonist Therapeutics, Inc.
PTGX
$103.88
$3.933.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 99.03% | -95.64% | 0.79% | 33.09% | -88.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.03% | -95.64% | 0.79% | 33.09% | -88.89% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 99.03% | -95.64% | 0.79% | 33.09% | -88.89% |
| SG&A Expenses | 13.11% | 27.70% | 9.57% | 11.77% | -21.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.00% | 31.77% | 10.85% | 10.77% | -2.08% |
| Operating Income | 81.11% | -139.72% | -11.98% | -8.37% | -109.36% |
| Income Before Tax | 119.57% | -132.71% | -16.98% | -10.57% | -105.53% |
| Income Tax Expenses | -- | -66.53% | -- | 125.44% | -- |
| Earnings from Continuing Operations | 132.46% | -133.71% | -18.46% | -13.57% | -105.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.46% | -133.71% | -18.46% | -13.57% | -105.62% |
| EBIT | 81.11% | -139.72% | -11.98% | -8.37% | -109.36% |
| EBITDA | 83.01% | -139.39% | -11.74% | -8.26% | -109.23% |
| EPS Basic | 131.39% | -132.81% | -14.73% | -9.63% | -105.43% |
| Normalized Basic EPS | 118.93% | -131.84% | -13.28% | -6.74% | -105.35% |
| EPS Diluted | 126.32% | -135.17% | -14.81% | -10.00% | -105.83% |
| Normalized Diluted EPS | 117.46% | -133.93% | -13.28% | -6.74% | -105.59% |
| Average Basic Shares Outstanding | 3.37% | 2.73% | 3.25% | 3.60% | 3.46% |
| Average Diluted Shares Outstanding | 11.96% | -3.58% | 3.25% | 3.60% | -0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |